Please assess the completion status of the following clinical trial:

Trial Title: Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histological documented uveal melanoma~* HLA-A2.1 phenotype (intervention arm)~* non-HLA-A2.1 phenotype (control arm)~* melanoma expressing gp100 and/or tyrosinase~* high risk genetic profile (loss of chromosome 3) determined by FISH~* interval since local treatment of uveal melanoma \< 12 months~* no signs of liver metastasis determined by diagnostic CT-abdomen~* normal serum LDH~* no signs of cerebral metastases~* bilirubin \< 25 micromol/l~* WHO performance scale 0-1~* age 18-75 years~* written informed consent~* expected adequacy of followup~* no pregnant or lactating women~Exclusion Criteria:~* history of second malignancy, except adequately treated basal cell carcinoma~* serious active infections~* autoimmune disease or organ allografts~* concomitant use of immunosuppressive drugs~* known allergy to shell-fish

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- dendritic cell vaccination (Type: EXPERIMENTAL): HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
- control arm (Type: NO_INTERVENTION): For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).

Based on this trial design, predict the completion outcome and termination type (if applicable).